Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages

FEBS Journal

Volumn 274, Issue 6, 2007, Pages 1530-1541

  Brown, Bronwyn E ^a   Rashid, Imran ^a   Van Reyk, David M ^b   Davies, Michael J ^a,c,d  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c University of Sydney   (Australia)

^d NONE   (Australia)

Author keywords

Aldehydes; Atherosclerosis; Foam cells; Human monocyte derived macrophages; Low density lipoproteins

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL ESTER; GLYCOSYLATED PROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENDOCYTOSIS; FEMALE; FOAM CELL; GLYCATION; HUMAN; HUMAN CELL; LIPID STORAGE; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; MACROPHAGE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; TIME;

APOLIPOPROTEIN B-100; CHOLESTEROL ESTERS; GLUCOSE; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MONOCYTES;

MURINAE;

EID: 33847374245     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2007.05699.x     Document Type: Article

References (65)

1. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820.
2. Eaton JW & Dean RT (2000) Diabetes and atherosclerosis. In Atherosclerosis (Dean RT & Kelly DT, eds), pp. 24-45. Oxford University Press, Oxford.
3. Ross R & Glomset JA (1976) The pathogenesis of atherosclerosis. N Engl J Med 295, 369-416.
4. Steinberg D (1997) Oxidative modification of LDL and atherogenesis. Circulation 95, 1062-1071.
5. Li AC & Glass CK (2002) The macrophage foam cell as a target for therapeutic intervention. Nat Med 8, 1235-1242.
6. Goldstein JL, Ho YK, Basu SK & Brown MS (1979) Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76, 333-337.
7. Khaw KT, Wareham N, Bingham S, Luben R, Welch A & Day N (2004) Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141, 413-420.
8. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH & Genuth S (2003) Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348, 2294-2303.
9. Lopes-Virella MF, Klein RL & Virella G (1996) Modification of lipoproteins in diabetes. Diabetes Metab Rev 12, 69-90.
10. Tomkin GH & Owens D (2001) Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Rev 17, 27-43.
11. Lyons TJ & Jenkins AJ (1997) Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 8, 174-180.
12. Baynes JW & Thorpe SR (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28, 1708-1716.
13. Thorpe SR & Baynes JW (2003) Maillard reaction products in tisue proteins: new products and new perspectives. Amino Acids 25, 275-281.
14. Zeng J & Davies MJ (2005) Evidence for the formation of adducts and S-(carboxymethyl) cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem Res Toxicol 18, 1232-1241.
15. Kawamura M, Heinecke JW & Chait A (1994) Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 94, 771-778.
16. Baynes JW & Thorpe SR (1999) Role of oxidative stress in diabetic complications - a new perspective on an old paradigm. Diabetes 48, 1-9.
17. Chisolm GM & Steinburg D (2000) The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28, 1815-1826.
18. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S & Babaei-Jadidi R (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375, 581-592.
19. Nagai R, Hayashi CM, Xia L, Takeya M & Horiuchi S (2002) Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J Biol Chem 348, 2294-2303.
20. Schleicher ED, Wagner E & Nerlich AG (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest 99, 457-468.
21. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R & Horiuchi S (1999) Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 142, 67-77.
22. Thornalley PJ, Langborg A & Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344, 109-116.
23. Atkins TW & Thornalley PJ (1989) Erythrocyte glyoxalase activity in genetically obese (ob/ob) and streptozotocin diabetic mice. Diabetes Res 11, 125-129.
24. Odani H, Shinzato T, Matsumoto Y, Usami J & Maeda K (1999) Increase in three α,β-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 256, 89-93.
25. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC & Witztum JL (1988) Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 37, 550-557.
26. Dean RT, Thomas SM, Vince G & Wolff SP (1986) Oxidation induced proteolysis and its possible restriction by some secondary protein modifications. Biomed Biochim Acta 45, 1563-1573.
27. Grant AJ, Jessup W & Dean RT (1992) Accelerated endocytosis and incomplete catabolism of radical-damaged protein. Biochim Biophys Acta 1134, 203-209.
28. Knott HM, Brown BE, Davies MJ & Dean RT (2003) Glycation and glycoxidation of low-density lipoproteins by glucose and low molecular weight aldehydes: formation of modified and oxidised proteins. Eur J Biochem 270, 3572-3582.
29. Brown BE, Dean RT & Davies MJ (2005) Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden foam cells. Diabetologia 48, 361-369.
30. Stadler N, Lindner RA & Davies MJ (2004) Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 24, 949-954.
31. Jinnouchi Y, Sano H, Nagai R, Hakamata H, Kodama T, Suzuki H, Yoshida M, Ueda S & Horiuchi S (1998) Glycolaldehyde-modified low density lipoprotein leads to foam cells via the macrophage scavenger receptor. J Biochem (Tokyo) 123, 1208-1217.
32. Guyton JR & Klump KF (1994) Development of the atherosclerosis core region - chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb 14, 1305-1314.
33. Schalkwijk CG, Vermeer MA, Stehouwer CDA, te Koppele J, Princen HMG & van Hinsbergh VWM (1998) Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein. Biochim Biophys Acta 1394, 187-198.
34. Lyons TJ, Klein RL, Baynes JW, Stevenson HC & Lopes-Virella MF (1987) Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from Type 1 (insulin dependent) diabetic patients: the influence of non-enzymatic glycosylation. Diabetologia 30, 916-923.
35. Horiuchi S, Sakamoto Y & Sakai M (2003) Scavenger receptors for oxidised and glycated proteins. Amino Acids 25, 283-292.
36. Jessup W, Mander EL & Dean RT (1992) The intracellular storage and turnover of apolipoprotein B of oxidised LDL in macrophages. Biochim Biophys Acta 1126, 167-177.
37. Dean RT, Fu S, Stocker R & Davies MJ (1997) Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 324, 1-18.
38. Miyata S, Liu B-F, Shoda H, Ohara T, Yamada H, Suzuki K & Kasuga M (1997) Accumulation of pyrraline-modified albumin in phagocytes due to reduced degradation by lysosomal enzymes. J Biol Chem 272, 4037-4052.
39. Mander EL, Dean RT, Stanley KK & Jessup W (1994) Apolipoprotein B of oxidised LDL accumulates in the lysosomes of macrophages. Biochim Biophys Acta 1212, 80-92.
40. Lougheed M, Zhang H & Steinbrecher UP (1991) Oxidised low density lipoprotein is resistant to cathepsins and accumulates within macrophages. J Biol Chem 266, 14519-14525.
41. Zeng J, Dunlop RA, Rodgers KJ & Davies MJ (2006) Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem J 398, 197-206.
42. Morgan PE, Dean RT & Davies MJ (2002) Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch Biochem Biophys 403, 259-269.
43. Grune T, Reinheckel T & Davies KJ (1997) Degradation of oxidized proteins in mammalian cells. FASEB J 11, 526-534.
44. Pacifici RE, Kono Y & Davies KJ (1993) Hydrophobicity as the signal for selective degradation of hydroxyl radical-modified hemoglobin by the multicatalytic proteinase complex, proteasome. J Biol Chem 268, 15405-15411.
45. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R & Hoff HF (2002) Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277, 49962-49988.
46. Haberland ME, Olch CL & Folgelman AM (1984) Role of lysines in mediating interaction of modified low density lipoproteins with the scavenger receptor of human monocyte macrophages. J Biol Chem 259, 11305-11311.
47. Nicholson AC, Frieda S, Pearce A & Silverstein RL (1995) Oxidised LDL binds to CD36 on human-monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol 15, 269-275.
48. Kawamura M, Heinecke JW & Chait A (2000) Increased uptake of α-hydroxy aldehyde-modified low density lipoprotein by macrophage scavenger receptors. J Lipid Res 41, 1054-1059.
49. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D et al. (1999) N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274, 31740-31749.
50. McLellan AC, Thornalley PJ, Benn J & Sonksen PH (1994) Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 87, 21-29.
51. Lapolla A, Flamini R, Dalla Vedova A, Senesi A, Reitano R, Fedele D, Basso E, Seraglia R & Traldi P (2003) Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin Chem Lab Med 41, 1166-1173.
52. Lo TW, Westwood ME, McLellan AC, Selwood T & Thornalley PJ (1994) Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with Nalpha-acetylarginine, Nalpha-acetylcysteine, and Nalpha-acetyllysine, and bovine serum albumin. J Biol Chem 269, 32299-32305.
53. Phillips SA & Thornalley PJ (1993) The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 212, 101-105.
54. Thornalley PJ, Jahan I & Ng R (2001) Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J Biochem (Tokyo) 129, 543-549.
55. Daugherty A, Dunn JL, Rateri DL & Heinecke JW (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94, 437-444.
56. Hazen SL, Hsu FF, d'Avignon A & Heinecke JW (1998) Human neutrophils employ myeloperoxidase to convert alpha-amino acids to a battery of reactive aldehydes: a pathway for aldehyde generation at sites of inflammation. Biochemistry 37, 6864-6873.
57. Proctor SD, Pabla CK & Mamo JCL (2000) Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis 1449, 315-322.
58. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL & Boren J (2002) Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417, 750-754.
59. Williams KJ & Tabas I (1998) The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 9, 471-474.
60. Bilheimer DW, Eisenberg G & Levy RI (1972) The metabolism of very low density lipoproteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta 260, 212-221.
61. Kee P, Caiazza D, Rye K-A, Barrett L, Morehouse L & Barter P (2006) Effect of inhibiting cholesteryl transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits. Arterioscl Thromb Vasc Biol 26, 884-890.
62. Nicholls S, Curtri B, Worthley S, Kee P, Rye K-A, Bao S & Barter P (2005) Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 25, 2416-2421.
63. Stevenson HC (1984) Isolation of human mononuclear leukocyte subsets by countercurrent centrifugal elutriation. Methods Enzymol 108, 242-249.
64. Garner B, Dean RT & Jessup W (1994) Human macrophage-mediated oxidation of low-density lipoprotein is delayed and independent of superoxide production. Biochem J 301, 421-428.
65. Fu S, Fu M-X, Baynes JW, Thorpe SR & Dean RT (1998) Presence of DOPA and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible sources of oxidative stress induced by AGE proteins. Biochem J 330, 233-239.